Copyright
©The Author(s) 2020.
World J Gastroenterol. Apr 14, 2020; 26(14): 1580-1593
Published online Apr 14, 2020. doi: 10.3748/wjg.v26.i14.1580
Published online Apr 14, 2020. doi: 10.3748/wjg.v26.i14.1580
Table 2 Targeting gastrointestinal cancer stem cell surface markers by monoclonal antibodies
| Targeting approach | Cancer model | Effects | Ref. |
| RG7576 mAb against CD44 | Solid tumors | Inhibited tumor growth and induced activation of macrophages | [23-26] |
| SWA11 against CD24 | Colorectal cancer | Reduced tumor cell proliferation and angiogenesis | [27,28] |
| G7 mAbs against CD24 | Liver cancer | Suppressed tumor growth | [29-31] |
| Catumaxomab (Removab®) mAb targeting EpCAM (CD326) | Gastric, colon cancers, pancreas | Activated immune cells (NK cells, macrophages, and T cells); prolonged survival period | [32-35] |
- Citation: Chivu-Economescu M, Necula LG, Matei L, Dragu DL, Neagu AI, Alexiu I, Bleotu C, Diaconu CC. Gastrointestinal cancer stem cells as targets for innovative immunotherapy. World J Gastroenterol 2020; 26(14): 1580-1593
- URL: https://www.wjgnet.com/1007-9327/full/v26/i14/1580.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i14.1580